 Leonard Seibold
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraocular Pressure | 35 | 2020 | 210 | 6.810 |
Why?
| | Glaucoma, Open-Angle | 14 | 2020 | 68 | 6.200 |
Why?
| | Glaucoma | 23 | 2020 | 131 | 5.950 |
Why?
| | Trabeculectomy | 12 | 2019 | 49 | 3.680 |
Why?
| | Phacoemulsification | 7 | 2019 | 55 | 2.670 |
Why?
| | Ocular Hypertension | 5 | 2019 | 40 | 2.470 |
Why?
| | Tonometry, Ocular | 18 | 2020 | 66 | 2.130 |
Why?
| | Cataract | 6 | 2019 | 132 | 1.910 |
Why?
| | Glaucoma Drainage Implants | 6 | 2020 | 30 | 1.770 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 17 | 1.700 |
Why?
| | Cataract Extraction | 5 | 2020 | 49 | 1.580 |
Why?
| | Visual Acuity | 8 | 2020 | 215 | 1.550 |
Why?
| | Laser Therapy | 3 | 2018 | 88 | 1.520 |
Why?
| | Trabecular Meshwork | 6 | 2019 | 65 | 1.300 |
Why?
| | Filtering Surgery | 6 | 2016 | 22 | 1.150 |
Why?
| | Ophthalmic Solutions | 5 | 2018 | 61 | 1.140 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 431 | 1.110 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 40 | 1.110 |
Why?
| | Nerve Fibers | 2 | 2012 | 81 | 0.970 |
Why?
| | Retinal Ganglion Cells | 2 | 2012 | 68 | 0.960 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 117 | 0.920 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 13 | 0.840 |
Why?
| | Ciliary Body | 2 | 2018 | 33 | 0.820 |
Why?
| | Pilocarpine | 1 | 2018 | 30 | 0.810 |
Why?
| | Laser Coagulation | 2 | 2018 | 48 | 0.810 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 10 | 0.730 |
Why?
| | Thiazines | 1 | 2017 | 9 | 0.730 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.730 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 26 | 0.700 |
Why?
| | Sulfonamides | 2 | 2017 | 369 | 0.690 |
Why?
| | Stents | 3 | 2018 | 427 | 0.680 |
Why?
| | Corneal Diseases | 1 | 2016 | 39 | 0.670 |
Why?
| | Endophthalmitis | 1 | 2016 | 26 | 0.670 |
Why?
| | Endoscopy | 2 | 2018 | 247 | 0.660 |
Why?
| | Cloprostenol | 1 | 2013 | 13 | 0.580 |
Why?
| | Postoperative Period | 6 | 2019 | 301 | 0.560 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1246 | 0.550 |
Why?
| | Drug Combinations | 3 | 2020 | 263 | 0.550 |
Why?
| | Prospective Studies | 9 | 2019 | 5432 | 0.540 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 13 | 0.540 |
Why?
| | African Americans | 1 | 2019 | 1011 | 0.530 |
Why?
| | Aged, 80 and over | 10 | 2019 | 6430 | 0.510 |
Why?
| | Prosthesis Implantation | 3 | 2020 | 122 | 0.500 |
Why?
| | Adipocytes | 1 | 2012 | 184 | 0.470 |
Why?
| | Humans | 43 | 2020 | 101421 | 0.470 |
Why?
| | Wound Healing | 2 | 2012 | 294 | 0.470 |
Why?
| | Blood Pressure | 2 | 2017 | 1588 | 0.470 |
Why?
| | Stainless Steel | 1 | 2010 | 18 | 0.460 |
Why?
| | Optic Disk | 1 | 2010 | 30 | 0.460 |
Why?
| | Aged | 14 | 2020 | 18548 | 0.460 |
Why?
| | Middle Aged | 16 | 2020 | 27254 | 0.450 |
Why?
| | Contact Lenses | 2 | 2020 | 5 | 0.450 |
Why?
| | Circadian Rhythm | 1 | 2013 | 443 | 0.420 |
Why?
| | Retrospective Studies | 12 | 2020 | 9641 | 0.420 |
Why?
| | Prednisolone | 2 | 2020 | 57 | 0.400 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2008 | 0.390 |
Why?
| | Software | 1 | 2012 | 560 | 0.390 |
Why?
| | Angiogenesis Inhibitors | 3 | 2015 | 209 | 0.390 |
Why?
| | Vision Disorders | 2 | 2020 | 109 | 0.370 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 157 | 0.360 |
Why?
| | Female | 20 | 2020 | 58733 | 0.360 |
Why?
| | Male | 20 | 2020 | 57621 | 0.350 |
Why?
| | Alkylating Agents | 2 | 2016 | 27 | 0.310 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.300 |
Why?
| | Glucocorticoids | 2 | 2020 | 509 | 0.290 |
Why?
| | Heart Rate | 2 | 2017 | 799 | 0.240 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.240 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.240 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 12 | 0.240 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 12 | 0.230 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 22 | 0.230 |
Why?
| | Amyloidosis | 1 | 2020 | 40 | 0.230 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 30 | 0.230 |
Why?
| | Visual Fields | 1 | 2020 | 79 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 2928 | 0.220 |
Why?
| | Eye Diseases | 1 | 2020 | 73 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2020 | 8507 | 0.210 |
Why?
| | Uveitis | 1 | 2019 | 92 | 0.210 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 432 | 0.210 |
Why?
| | Preoperative Period | 1 | 2019 | 109 | 0.200 |
Why?
| | Mitomycin | 2 | 2016 | 40 | 0.200 |
Why?
| | Biosensing Techniques | 1 | 2020 | 112 | 0.200 |
Why?
| | Adult | 11 | 2020 | 29687 | 0.200 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.200 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 11 | 0.200 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.200 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.200 |
Why?
| | Refraction, Ocular | 1 | 2018 | 17 | 0.200 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 9 | 0.200 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 24 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2015 | 486 | 0.180 |
Why?
| | Time Factors | 2 | 2019 | 7096 | 0.170 |
Why?
| | Fluoroquinolones | 1 | 2016 | 41 | 0.170 |
Why?
| | Young Adult | 4 | 2019 | 9994 | 0.170 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 314 | 0.160 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 11 | 0.160 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 106 | 0.160 |
Why?
| | Device Removal | 1 | 2016 | 113 | 0.160 |
Why?
| | Drug Packaging | 1 | 2015 | 57 | 0.150 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 5 | 0.150 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 54 | 0.150 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 22 | 0.150 |
Why?
| | Travoprost | 1 | 2013 | 13 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2012 | 2643 | 0.150 |
Why?
| | Ethnic Groups | 1 | 2018 | 620 | 0.150 |
Why?
| | Patient Preference | 1 | 2016 | 160 | 0.140 |
Why?
| | Antimetabolites | 1 | 2012 | 29 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4641 | 0.130 |
Why?
| | Sleep | 1 | 2019 | 615 | 0.130 |
Why?
| | Anterior Chamber | 1 | 2012 | 19 | 0.130 |
Why?
| | Adenoma | 1 | 2014 | 179 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 685 | 0.130 |
Why?
| | Conjunctiva | 1 | 2012 | 52 | 0.130 |
Why?
| | Prostaglandins F | 1 | 2011 | 22 | 0.130 |
Why?
| | Blister | 1 | 2012 | 44 | 0.130 |
Why?
| | Tissue Donors | 1 | 2012 | 289 | 0.120 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 38 | 0.120 |
Why?
| | Equipment Safety | 1 | 2010 | 45 | 0.110 |
Why?
| | Torque | 1 | 2010 | 63 | 0.110 |
Why?
| | Dexamethasone | 1 | 2012 | 309 | 0.110 |
Why?
| | Medication Adherence | 1 | 2015 | 486 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 965 | 0.110 |
Why?
| | Cohort Studies | 1 | 2019 | 4477 | 0.100 |
Why?
| | Cell Survival | 1 | 2012 | 1107 | 0.100 |
Why?
| | Reference Values | 1 | 2010 | 883 | 0.100 |
Why?
| | Inflammation | 1 | 2018 | 2116 | 0.090 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 848 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1209 | 0.090 |
Why?
| | Adolescent | 3 | 2020 | 17194 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 3511 | 0.080 |
Why?
| | Administration, Topical | 2 | 2016 | 149 | 0.080 |
Why?
| | Intravitreal Injections | 2 | 2015 | 36 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2012 | 2262 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2012 | 4316 | 0.070 |
Why?
| | Rabbits | 2 | 2012 | 723 | 0.060 |
Why?
| | Ocular Hypotension | 1 | 2019 | 7 | 0.050 |
Why?
| | Ophthalmology | 1 | 2019 | 36 | 0.050 |
Why?
| | Histological Techniques | 1 | 2018 | 37 | 0.050 |
Why?
| | Reoperation | 1 | 2020 | 559 | 0.050 |
Why?
| | Risk Assessment | 2 | 2020 | 2871 | 0.050 |
Why?
| | Microscopy | 1 | 2018 | 101 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 142 | 0.050 |
Why?
| | Perioperative Care | 1 | 2019 | 193 | 0.050 |
Why?
| | Fibrosis | 1 | 2018 | 344 | 0.040 |
Why?
| | Medication Errors | 1 | 2015 | 104 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 271 | 0.040 |
Why?
| | Iris | 1 | 2013 | 19 | 0.040 |
Why?
| | Disease Progression | 1 | 2020 | 2374 | 0.030 |
Why?
| | Goblet Cells | 1 | 2012 | 18 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 460 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3209 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 144 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 292 | 0.030 |
Why?
| | Postoperative Care | 1 | 2012 | 287 | 0.030 |
Why?
| | Collagen | 1 | 2012 | 400 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2020 | 2049 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2232 | 0.020 |
Why?
| | Animals | 3 | 2012 | 33965 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 4084 | 0.020 |
Why?
| | Child | 1 | 2020 | 15095 | 0.020 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|